Perhaps it is time for a change in policy on lung cancer screening

David F. Yankelevitz, MD
Professor of Radiology, New York-Presbyterian Hospital, New York, NY; Investigator, International Early Lung Cancer Action Program

Address: David F. Yankelevitz, MD, New York-Presbyterian Hospital, 520 East 70th Street, New York, NY 10021; e-mail: dyankele@med.cornell.edu

The author has indicated that he owns stock in and serves as a consultant for the PneumRx corporation.

David F. Yankelevitz, MD
Professor of Radiology, New York-Presbyterian Hospital, New York, NY; Investigator, International Early Lung Cancer Action Program

Address: David F. Yankelevitz, MD, New York-Presbyterian Hospital, 520 East 70th Street, New York, NY 10021; e-mail: dyankele@med.cornell.edu

The author has indicated that he owns stock in and serves as a consultant for the PneumRx corporation.

David F. Yankelevitz, MD
Professor of Radiology, New York-Presbyterian Hospital, New York, NY; Investigator, International Early Lung Cancer Action Program

Address: David F. Yankelevitz, MD, New York-Presbyterian Hospital, 520 East 70th Street, New York, NY 10021; e-mail: dyankele@med.cornell.edu

The author has indicated that he owns stock in and serves as a consultant for the PneumRx corporation.